Gilde closes €250m growth fund

Utrecht-based Gilde Healthcare has companies such as Galapagos, Ablynx and uniQure in its portfolio. Over the years, the investment firm has raised around €800m in dedicated healthcare funds. The latest fund, Gilde Healthcare IV, closed at its hard cap. It is backed by international investors, among them Royal Philips, which acted as a cornerstone investor as in the previous Gilde Healthcare III fund. Johnson & Johnson Innovation – JJDC, Inc. joined as a new corporate investor. Additional investors include fund-of-funds, sovereign funds such as Danish Growth Fund, endowments, family offices, entrepreneurs and Gilde partners. The European Investment Fund also participated in the fund through several of its funding programmes, including the European Recovery Programme and Dutch Venture Initiative II.

The Gilde Healthcare IV Fund will make equity investments in a single portfolio company of between €15-25m. “The healthcare landscape in the US and Europe is changing, driven by the need for more patient centric care and a much sharper focus on value,” commented Pieter van der Meer, Managing Partner of Gilde Healthcare. “With our new fund, we will continue to pursue our differentiated investment strategy of backing growth and later stage companies developing novel technologies or therapeutics that enable better healthcare outcomes at reduced costs."

© european-biotechnology-news.com/um